A Phase 2 interventional study of Afimkibart and Placebo in Atopic Dermatitis, sponsored by Hoffmann-La Roche. Active, not recruiting at 52 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 639 studies in Dermatitis, Atopic with a site in United States — 78 open to participants now, 117 under way, 18 of them phase 3. Dermatitis, Atopic · United States.
Among the 639 studies in Dermatitis, Atopic with a site in United States, this one is the 200th largest by enrollment of the 544 interventional ones that give a count, is one of 41 that started in 2025, is one of 202 in phase 2, reaches primary completion later than 16 of the 115 other live ones, and was the 579th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →78 of the 639 studies in Dermatitis, Atopic with a site in United States are open now. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 12–120
Weill Medical College of Cornell University · Sites in United States
Ages 13–17
Arcutis Biotherapeutics, Inc. · Sites in United States
Ages 6+
Triveni Bio · Sites in United States, Canada, Ukraine
Ages 18–75
Pfizer · Sites in United States, Canada, Japan and 1 more country
Ages 12+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
639 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 97 · Phase 2 221 · Phase 3 107 · Phase 4 70
First in 1996; this study’s year is marked. 41 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 162 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 96 across the 544 interventional studies, 155 across the 94 observational. Of the 491 that completed or were terminated, 265 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
429 of 639 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Hoffmann-La Roche has 6 studies filed under Dermatitis, Atopic — fewer than ten, so there is no comparison to draw.
43 of the studies in Dermatitis, Atopic with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06389136Phase 3AbbVieA Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab | 2026-11 |
| NCT07355075Phase 3Turn TherapeuticsA Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema) | 2027-01-20 |
| NCT07265479Phase 3Organon and CoA Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis | 2027-08 |
| NCT06241118Phase 3SanofiA Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor | 2027-09-30 |
| NCT06395948Apogee Therapeutics, Inc.A Study Evaluating APG777 in Atopic Dermatitis | 2026-11 |
Add all 43 to your calendar (.ics) → With an account.
Among the 639 studies in Dermatitis, Atopic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the efficacy and safety of Afimkibart (also known as RO7790121) in participants with moderate to severe atopic dermatitis (AD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive afimkibart via subcutaneous (SC) injection.
Drug: Afimkibart
Participants will receive afimkibart via SC injection.
Drug: Afimkibart
Participants will receive afimkibart via SC injection.
Drug: Afimkibart
Participants will receive placebo via SC injection.
Drug: Placebo
Afimkibart will be administered as SC injection.
Also known as: PF-06480605, RVT-3101, RO7790121
Placebo will be administered as SC injection.
Percentage of Participants who Achieve Eczema Area and Severity Index-75 (EASI-75) Response (>= 75% Improvement from Baseline) at Week 16
Time frame: Baseline and Week 16
Percentage of Participants who Achieve Investigator Global Assessment (IGA) Score of Clear (0) or Almost Clear (1) with >= 2-Grade Improvement at Week 16 and Week 32
Time frame: At Week 16 and Week 32
Percentage of Participants who Achieve EASI-75 Response at Week 32
Time frame: At Week 32
Percentage of Participants who Achieve EASI-90 Response at Week 16 and Week 32
Time frame: At Week 16 and Week 32
Percent Change from Baseline in EASI by Visit
Time frame: Baseline up to end of study (approximately 1 year)
Percent Change from Baseline in Peak Pruritus Numerical Rating Scale (NRS) Score by Visit
Time frame: Baseline up to end of study (approximately 1 year)
Change from Baseline in Dermatology Quality of Life Index at Week 16, Week 32 and by Visit
Time frame: Baseline, weeks 4, 10, 16, 22 and 32
Percentage of EASI-75 Responders at Week 16
Time frame: At Week 16
Percentage of Participants with Adverse Events
Time frame: Baseline up to end of study (approximately 1 year)
Serum Concentration of Afimkibart at Specified Timepoints
Time frame: Weeks 0, 2, 4, 6, 10, 14, 16, 18, 22, 26, 30, 32 and monthly at weeks 4, 8 and 12 after treatment discontinuation.
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
No publications or documents are linked to this record.
Ran from Apr 2025 to primary completion in Jul 2026, 15 months.
Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 15 months is above that.
Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Afimkibart